Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCA 2A

Journal of Urology

Volumn 162, Issue 6, 1999, Pages 2192-2199

  Zhao, Xiao Yan ^b   Boyle, Bryan ^b   Krishnan, Aruna V ^b   Navone, Nora M ^b   Peehl, Donna M ^b   Feldman, David ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Androgen receptor mutations; LNCaP; MDA PCa 2a; Prostate; PSA

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; CELL DNA; ESTRADIOL; METRIBOLONE; MUTANT PROTEIN; PRASTERONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SEQUENCE ANALYSIS;

EID: 0032743557     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68158-X     Document Type: Article

References (19)

1. Smith, J.: Current concepts in the treatment of cancer of the prostate. In: Hormones and Cancer. Edited by W. Vedeckis. Boston: Birkhauser, pp. 379-393, 1996.
2. Barrack, E.: Androgen receptor mutations in prostate cancer. Mt. Sinai. J. Med., 63: 403, 1996.
3. Tang, D. and Porter, A.: Target to apoptosis: a hopeful weapon for prostate cancer. Prostate, 32: 284, 1997.
4. Gottlieb, B., Lehvaslaiho, H., Beitel, L., Lumbroso, R., Pinsky, L. and Trifiro, M.: The androgen receptor gene mutations database. Nucleic Acids Res., 26: 234, 1998.
5. Veldscholte, J., Voorhorst-Ogink, M., Vries, J., Rooij, H., Trapman, J. and Mulder, E.: Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim. Biophys. Acta, 1052: 187, 1990.
6. Gaddipati, J., McLeod, D., Heidenberg, H., Sesterhenn, I., Finger, M., Moul, J. and Srivastava, S.: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res., 54: 2861, 1994.
7. Navone, N., Olive, M., Ozen, M., Davis, R., Troncoso, P. and Tu, S.: Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res., 3: 2493, 1997.
8. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinol., 138: 3290, 1997.
9. Burton, K.: A study of conditions and mechanisms of the diphenyl amine colorimetric estimation of deoxyribonucleic acid. Biochem. J., 62: 315, 1956.
10. Bradford, M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72: 248, 1976.
11. Lubahn, D., Brown, T., Simental, J., Higgs, H., Migeon, C., Wilson, E. and French, F.: Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc. Natl. Acad. Sci. USA, 86: 9534, 1989.
12. Horoszewicz, J., Leong, S., Kawinski, E., Karr, J., Rosenthal, H., Chu, T., Mirand, E. and Murphy, G.: LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809, 1983.
13. MacIndoe, J., West, E. and Petrow, V.: Comparative studies of 5 alpha-reductase inhibitors within MCF-7 human breast cancer cells. J. Steroid Biochem., 20: 1095, 1984.
14. Wurtz, J., Bourguet, W., Renaud, J., Vivat, V., Chambon, P., Moras, D. and Gronemeyer, H.: A canonical structure for the ligand-binding domain of nuclear receptors [see comments] [published erratum appears in Nat. Struct. Biol., 3: 206, 1996]. Nat. Struct. Biol., 3: 87, 1996.
15. Quigley, C., De Bellis, A., Marschke, K., el-Awady, M., Wilson, E. and French, F.: Androgen receptor defects: historical, clinical, and molecular perspectives [published erratum appears in Endocr. Rev., 16: 546, 1995]. Endocr. Rev., 16: 271, 1995.
16. Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S. and Shimazaki, J.: Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46: 759, 1993.
17. Pinsky, L., Trifiro, M., Kaufman, M., Beitel, L., Mhatre, A., Kazemi-Esfarjani, P., Sabbaghian, N., Lumbroso, R., Alvarado, C. and Vasiliou, M.: Androgen resistance due to mutation of the androgen receptor. Clin. Invest. Med., 15: 456, 1992.
18. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J. and Kallioniemi, O.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401, 1995.
19. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T. and Kallioniemi, O.: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314, 1997.